Post Banksy exhibition – Wellington has now gained an extra cone. It reminds me of what cell/compartment should we be targeting in oncology trials.

Some of the challenges with personalised medicine is we often see companies either treating a targeted therapy in an untargeted fashion thereby diluting the signal or enriching for one not yet conclusively and clinically established.

In both cases, the results are inevitably suboptimal.

Additionally, not all drugs within the same category are the same.  They often have dissimilar scaffolds or target different cells and compartments, all of which can have a positive or negative impact on clinical outcomes.

In our latest post, we explore and discuss emerging insights around strategies undertaken in clinial trials and how they may offer some clues for certain company readouts over the next quarter…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by